Phase Ib Study of BYL719 (Alpelisib) in Combination With Androgen Receptor Inhibitor (Enzalutamide) in Patients With Androgen Receptor (AR)-Positive and PTEN Positive Metastatic Breast Cancer
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 07 Feb 2019
At a glance
- Drugs Alpelisib (Primary) ; Enzalutamide (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions
- 31 Jan 2019 Planned End Date changed from 1 Jan 2021 to 1 Dec 2020.
- 31 Jan 2019 Planned primary completion date changed from 1 Jan 2021 to 1 Dec 2020.
- 31 Jan 2019 Planned initiation date changed from 1 Jan 2019 to 31 Mar 2019.